Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,208.12 +80.43 (+7.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors ↗
It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market. 
Via The Motley Fool
News headline image
Why WeightWatchers (WW) Stock Is Trading Up Today
What Happened? Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Wat... 
Via StockStory
Topics Artificial Intelligence Bonds Credit Cards
News headline image
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said... 
Via MarketBeat
News headline image
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday ↗
Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Via Chartmill
News headline image
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies ↗
Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion. 
Via Benzinga
News headline image
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success ↗
Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Reasons Eli Lilly Remains a Buy ↗
The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher. 
Via The Motley Fool
News headline image
Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock ↗
Eli Lilly is far from a one-trick pony. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Elizabeth Warren Singles Out Micron, Dell And Eli Lilly As Just 3 Of The 3000+ Trades Trump Made: 'Looks Like An Absurd Level Of Corruption' ↗
Sen. Elizabeth Warren questioned Trump's trading activity, citing potential conflicts of interest and renewing calls for a stock-trading ban. 
Via Benzinga
Topics Government
News headline image
Avascular Necrosis Market Size, Industry Share By 2035 ↗
The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, 
Via Talk Markets
Topics Economy
News headline image
Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Better ↗
Can any company pose a serious challenge to Eli Lilly in the weight-loss market? 
Via The Motley Fool
News headline image
Here's What I Think Is Really Going on With Novo Nordisk Stock ↗
There is light at the end of the tunnel. 
Via The Motley Fool
News headline image
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years ↗
SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗
This particular sector may suit cautious and aggressive investors. 
Via The Motley Fool
News headline image
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape 
Via TheNewswire.com
News headline image
Bull vs. Bear: The Quick Take on Viking Therapeutics Stock ↗
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals. 
Via The Motley Fool
News headline image
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street ↗
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year. 
Via The Motley Fool
Topics ETFs Intellectual Property Stocks
News headline image
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗
Eli Lilly's pipeline is an embarrassment of riches. 
Via The Motley Fool
News headline image
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 ↗
It is finally bouncing back after several challenging years. 
Via The Motley Fool
News headline image
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? ↗
Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact. 
Via The Motley Fool
Topics ETFs
News headline image
Nvidia's Jensen Huang Just Gave Marvell Technology a Huge Boost ↗
Huang has lofty expectations for Marvell Technology. 
Via The Motley Fool
News headline image
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage ↗
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health. 
Via MarketBeat
News headline image
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down ↗
An upcoming trial result could change how investors think about the weight-loss drug market. 
Via The Motley Fool
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story. 
Via The Motley Fool
Topics ETFs
News headline image
State Street's Health Care ETF Tops Invesco's on Yield and Returns ↗
Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors. 
Via The Motley Fool
Topics ETFs
News headline image
Trump Said 'Micron's Great'—And Now Micron's Worth More Than Walmart, Eli Lilly, Berkshire Hathaway ↗
Micron Technology just became the 12th-biggest company in the world, bigger than Berkshire Hathaway. UBS sees another 56% upside as June 24 earnings near. 
Via Benzinga
Topics Government
News headline image
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ ↗
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S.... 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullish ↗
David Ricks was addressing the pharmaceutical titan's latest hot product. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.